New Treatment For Esophageal Cancer 2022 - FDA Approved
Esophageal cancer is the 8th most common form of cancer. However, there have been continuous advancement in new treatment for esophageal cancer. Read on to know the latest updates of 2022.
Table of Contents :
- FDA Approves Nivolumab/Chemo and Nivolumab/Ipilimumab
- More detail about CheckMate 648
- Key Findings of the New Treatment & Possible Benefits
Esophageal cancer is a form of common gastrointestinal malignancy that originates in the esophagus. There are two most common types of esophageal cancer:
- Squamous cell carcinoma
Adenocarcinoma occurs closer to the stomach. On the other hand, squamous cell carcinoma occurs mainly in the upper part of the esophagus.
Esophageal cancer is the 8th most commonly diagnosed form of cancer worldwide. As per reports, it is the 13th most common cancer among women and the 7th most common type of cancer in men. 2020 reported more than 6 lakh cases of esophageal cancer around the world. According to WHO, GLOBOCAN 2018, it is the 6th most common cancer in India, with an incidence rate of 5.04%. In India, it is the 6th common cancer in females and 5th in males.
However, the advancement of medical science has opened new avenues of treatment for esophageal cancer. In the past few years, we saw several techniques and drugs for esophageal cancer cures getting FDA approval. 2022 is no different. Revolutionary immunotherapy for esophageal cancer has created a buzz in oncology. Nivolumab, sold under the brand name Opdivo, Bristol-Myers Squibb Company, got FDA approval on May 27, 2022, as a first-line treatment.
Read on to learn more about this new treatment for esophageal cancer
FDA Approves Nivolumab/Chemo and Nivolumab/Ipilimumab
FDA approved nivolumab (Opdivo, Bristol-Myers Squibb Company) plus chemotherapy and nivolumab plus ipilimumab (Yervoy, Bristol-Myers Squibb Company) as a treatment for patients with advanced or metastatic esophageal cancer. These new cancer cure therapies are especially beneficial for those who cannot undergo esophageal cancer surgery.
The approval by the FDA was based on the phase 3 CheckMate 648 trial (NCT03143153). In the trial, researchers used nivolumab in combination with ipilimumab or chemotherapy for esophageal cancer. The results showed that patients given nivolumab had better overall survival (OS) than those who only received chemotherapy.
To give you more clarity, we have mentioned how the study of this new esophageal cancer treatment worked.
More detail about CheckMate 648
Researchers performed CheckMate 648 with 970 randomized patients. All the patients had advanced or metastatic squamous cell carcinoma untreatable through esophagus surgery. There were three categories in the trial.
- The first was administered a combination of nivolumab and chemotherapy.
- The second group in the trial underwent immunotherapy only and took a combination of nivolumab-ipilimumab.
- The third group took only chemotherapy for esophageal cancer.
Researchers presented their analysis at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial results showed that the nivolumab-chemotherapy combination conferred longer overall survival (OS) vs. chemotherapy alone among all patients.
Key Findings of the New Treatment & Possible Benefits
- The two immunotherapy-based combinations are the new hope for many with advanced esophageal cancer.
- It is the world's first treatment regimen without chemotherapy to benefit patients with previously untreated esophageal cancer. Even the combination of nivolumab and ipilimumab significantly prolonged OS against those who took only chemotherapy.
- The trial results also showed positive effects in patients with tumor cell PD-L1 expression of 1% or greater. PD-1 is a protein in T cells and plays a significant role in our bodies immune system. When PD-1 binds to another protein called PD-L1, it decreases the ability of T cells to kill cancer cells. Immunotherapy is beneficial in cases where cancer cells have a high amount of PDL1.
- In the trial CheckMate 648, 48% of the patients in the chemotherapy group and 49% in the combination therapy groups had PD-L1 positive tumors. A follow-up of 13 months showed overall survival was better amongst patients in both combination groups whose tumors were PD-L1 positive. The combination groups also had a percentage of patients whose tumors shrank.
|Treatment Group||All Participants||Participants with PD-L1+ tumours|
|Nivolumab + Chemotherapy||13.2 months||15.4 months|
|Nivolumab + Ipilimumab||12.8 months||13.7 months|
|Chemotherapy alone||10.7 months||9.1 months|
These new therapies can potentially improve the outlook for patients and families affected by esophageal cancer. Such innovation brings us closer to effective, lasting cures for esophageal cancer.
Question and Answers (394)
Sir what is malignant ascites cancer life expectancy
What treatment of uterus cancer in India is available?
Is ascites ovarian cancer the last stage?
My father age 67. He is suffer collon cancer. He is colestomy operation done in March 22. What is next treatment???
I m 21 years old female my left nipples always cracks and peels out and little blood flesh which has come out of nipples is seen I m very tensed I have consulated two doctors they oitment is still thing from three years
If the cracking of nipple is not responding to ointment what needs to be ruled out is a Paget's disease of the nipple. This requires a clinical examination by a breast surgeon and he or she can guide you further on the same.
New Lung Cancer Treatment 2022- FDA ApprovedLung cancer begins in your lungs and is responsible for causing many other cancers. Lung cancer is a significant cause of death. Researchers were continuously working to develop a new lung cancer treatment. Recently, the FDA has approved a few of the latest drugs for lung cancer treatment. This article has everything you need to know about the latest lung cancer treatment medications.
New Prostate Cancer Treatment 2022- FDA Approved Advanced Prostate Cancer treatmentIn 2022, treatment for prostate cancer took a big step forward when the US Food and Drug Administration approved a new treatment. That's the view of many in the medical world right now, who are working tirelessly on new diagnostic techniques, treatments, and even preventative measures for prostate cancer. If we continue at our current pace of advancement, these optimists believe that we can almost eliminate the risk of this common cancer among men. So what will change in 2022? Let's take a look…
New Pancreatic Cancer Treatment 2022: A New Breakthrough to Defeat the Big CPancreatic cancer is one of the most common cancers in the world. Since 2000, the annual incidence of pancreatic cancer has increased by around 1%. In 2020, an estimated 495,000 people will be diagnosed with pancreatic cancer worldwide. Read till the end to learn about a potential new pancreatic cancer treatment.
New Breast Cancer Treatment in 2022- FDA ApprovedDid you know? The survival rates for breast cancer are usually high when the cancer is detected at an early stage. However, 50% to 60% of cases are diagnosed only at advanced stages, which makes the treatment more critical and incurable at times. Read more to know everything in detail about the new breast cancer treatment approved by FDA in 2022.
Best Ovarian Cancer Treatment in the WorldAbout 3 out of 4 women live for at least one year after the diagnosis of ovarian cancer. This makes it necessary for women to seek the best ovarian cancer treatment from the best possible hospitals. So, for your convenience, we have listed some of the best ovarian cancer hospitals in the world. So make sure to read this article to the end!
New Cancer Treatment: The Hope of Cancer Free World On Its wayThere are currently more than 100 types of cancer, and the disease affects more people every year. The good news is that the cancer mortality rate has decreased over the last 25 years. However, it continues to be one of the world's most common causes of death. Although various treatment options are available, many have adverse side effects. Fortunately, brilliant minds are working on new ways to detect, develop new cancer drugs to treat, and manage cancer so patients can lead happy, healthy lives following their diagnosis. Let's look at how innovations in oncology may change treatment for cancer patients in near future.